A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) (StrateGIST FrontLine)

Principal Investigator

Leonidas Mavroeidis

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1013762